Streetbeat News

Analyst Ratings

ZS

Canaccord Genuity analyst Michael Walkley maintains a 'Buy' rating on Zscaler (NASDAQ:ZS) and raises the price target from $160 to $172.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:24 pm

AMTX

Stifel analyst Derrick Whitfield has maintained a 'Buy' rating on Aemetis (NASDAQ:AMTX) and raised the price target from $9 to $10.5.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:22 pm

CMPS

Cantor Fitzgerald analyst Jonathan Fiore has reiterated an Overweight rating on Compass Pathways (NASDAQ:CMPS) and maintained a $21 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:22 pm

BIG

CBRL

FL

The most accurate Wall Street analysts recommend holding three consumer stocks with over 6% dividend yields: Big Lots, Inc. (BIG), Foot Locker, Inc. (FL), and Cracker Barrel Old Country Store, Inc. (CBRL). These recommendations are based on the companies' high free cash flows and high dividend payouts. Recent news for each company includes upcoming Q2 results for BIG and FL, and a CEO transition for CBRL.

Portfolio Pulse from Lisa Levin

August 22, 2023 | 1:22 pm

BIVI

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on BioVie and maintained a price target of $11.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:22 pm

KR

LLY

PFE

RAD

WMT

Retailers with pharmacy businesses, including Walmart, Kroger, and Rite Aid, are seeing a boost in sales due to increased demand for prescription weight loss drugs. However, the profitability of these treatments is minimal for retail pharmacies. The weight loss drug market could reach $200 billion by 2030, attracting interest from drugmakers like Eli Lilly and Pfizer. The increased sales of these drugs may lead to additional purchases in various categories, offsetting the margin challenges in the pharmacy division.

Portfolio Pulse from Vandana Singh

August 22, 2023 | 1:21 pm

APP

Jefferies has upgraded AppLovin's stock from Hold to Buy and raised its price target from $20 to $50. This has resulted in AppLovin shares trading higher.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 1:21 pm

AXSM

Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $108.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:21 pm

ARCT

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Arcturus Therapeutics (NASDAQ:ARCT) and maintained a $54 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:20 pm

ANNX

Cantor Fitzgerald analyst Pete Stavropoulos has reiterated an Overweight rating on Annexon (NASDAQ:ANNX) and maintained a $13 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 1:19 pm